2022
DOI: 10.1182/blood.2021014232
|View full text |Cite
|
Sign up to set email alerts
|

Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients

Abstract: Three reports address the protection of the vulnerable population of patients with hematologic malignancies in the face of the ongoing COVID pandemic. The reports suggest that some patients who fail to mount a B-cell response to vaccine may nevertheless have protective T cell responses. As a group, these reports suggest that patients should continue to be immunized with additional doses to attempt to improve immune response but that they need to maintain the precautions recommended for the unvaccinated.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

13
112
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
7

Relationship

4
3

Authors

Journals

citations
Cited by 67 publications
(125 citation statements)
references
References 16 publications
13
112
0
Order By: Relevance
“…Of note, 4 of the 5 patients who failed to seroconvert after the two first doses of the vaccine responded to the booster dose. These data are in line with prior reports assessing binding Ab responses to a third dose of mRNA vaccine in allo-HCT patients ( Redjoul et al., 2021a ; Maillard et al., 2022 ).…”
Section: Main Textsupporting
confidence: 92%
See 3 more Smart Citations
“…Of note, 4 of the 5 patients who failed to seroconvert after the two first doses of the vaccine responded to the booster dose. These data are in line with prior reports assessing binding Ab responses to a third dose of mRNA vaccine in allo-HCT patients ( Redjoul et al., 2021a ; Maillard et al., 2022 ).…”
Section: Main Textsupporting
confidence: 92%
“…Allogeneic hematopoietic stem cell transplant (allo-HCT) recipients are particularly at risk of severe COVID-19. In addition, they have lower serological response to two doses of mRNA vaccines as compared to healthy individuals ( Redjoul et al., 2021a ; Canti et al., 2021 ; Maillard et al., 2022 ). Whether they are protected following vaccination against the Delta and Omicron variants remains to be established.…”
Section: Main Textmentioning
confidence: 99%
See 2 more Smart Citations
“…(2021) showed that a third dose of BNT162b2 mRNA vaccine led to a significant increase in anti-SARS-CoV-2 IgG antibodies (from 737 AU/mL to 11,099 AU/mL; p = 0.00069) in 42 alloHCT recipients. Maillard et al. (2022) showed that 41% of patients (29/70) developed a detectable response after the third dose after not responding to the first two doses.…”
Section: Main Textmentioning
confidence: 99%